Literature DB >> 32381293

The Impact of Radiation Therapy on Innate and Adaptive Tumor Immunity.

Andrew Brandmaier1, Silvia C Formenti2.   

Abstract

The role of radiation therapy for cancer is evolving as its biologic effects on tumors becomes more clearly defined. Traditionally, radiobiology models dose-response curves based on direct cytocidal effects of radiation on tumor cells. However, a more dynamic picture is emerging of the impact of radiation on the tumor microenvironment and the patient's innate and adaptive immune system. Radiation produces damage associated molecular patterns that activate innate immune receptors leading to a cascade of downstream signals. These signals alter the tumor infiltrating immune population, modulate immune cell activation status, and enhance antigen presentation. The changes are conducive to an adaptive immune response with the generation of antitumor T cells. Early findings from clinical trials incorporating radiation and immune checkpoint inhibitors show promising synergy between the 2 modalities. As more data matures from ongoing trials, clinicians can refine new strategies for using radiation together with immunotherapy to achieve improved clinical outcomes.
Copyright © 2019. Published by Elsevier Inc.

Entities:  

Year:  2020        PMID: 32381293     DOI: 10.1016/j.semradonc.2019.12.005

Source DB:  PubMed          Journal:  Semin Radiat Oncol        ISSN: 1053-4296            Impact factor:   5.934


  9 in total

1.  Rethinking the immunotherapy numbers game.

Authors:  Rebecca A Bekker; Mohammad U Zahid; Jennifer M Binning; Bryan Q Spring; Patrick Hwu; Shari Pilon-Thomas; Heiko Enderling
Journal:  J Immunother Cancer       Date:  2022-07       Impact factor: 12.469

2.  Novel Carbon Ion and Proton Partial Irradiation of Recurrent Unresectable Bulky Tumors (Particle-PATHY): Early Indication of Effectiveness and Safety.

Authors:  Slavisa Tubin; Piero Fossati; Antonio Carlino; Giovanna Martino; Joanna Gora; Markus Stock; Eugen Hug
Journal:  Cancers (Basel)       Date:  2022-04-29       Impact factor: 6.575

3.  Intermittent radiotherapy as alternative treatment for recurrent high grade glioma: a modeling study based on longitudinal tumor measurements.

Authors:  Sarah C Brüningk; Jeffrey Peacock; Christopher J Whelan; Renee Brady-Nicholls; Hsiang-Hsuan M Yu; Solmaz Sahebjam; Heiko Enderling
Journal:  Sci Rep       Date:  2021-10-12       Impact factor: 4.379

Review 4.  Modulation of the Complement System by Neoplastic Disease of the Central Nervous System.

Authors:  Steven K Yarmoska; Ali M Alawieh; Stephen Tomlinson; Kimberly B Hoang
Journal:  Front Immunol       Date:  2021-10-04       Impact factor: 7.561

5.  Durvalumab as Consolidation Therapy in Post-Multimodal Interventional Treatment for Patients with Advanced Solid Tumors: A Preliminary Study.

Authors:  Yuanming Li; Runqi Guo
Journal:  J Oncol       Date:  2022-03-15       Impact factor: 4.375

Review 6.  Nonresolving inflammation redux.

Authors:  Carl Nathan
Journal:  Immunity       Date:  2022-04-12       Impact factor: 43.474

Review 7.  Mathematical modeling of radiotherapy and its impact on tumor interactions with the immune system.

Authors:  Rebecca Anne Bekker; Sungjune Kim; Shari Pilon-Thomas; Heiko Enderling
Journal:  Neoplasia       Date:  2022-04-19       Impact factor: 6.218

Review 8.  Irradiation immunity interactions.

Authors:  David A Simon Davis; Ines I Atmosukarto; Jessica Garrett; Katharine Gosling; Farhan M Syed; Ben Jc Quah
Journal:  J Med Imaging Radiat Oncol       Date:  2022-03-08       Impact factor: 1.667

9.  The Kinetics of FMS-Related Tyrosine Kinase 3 Ligand (Flt-3L) during Chemoradiotherapy Suggests a Potential Gain from the Earlier Initiation of Immunotherapy.

Authors:  Łukasz Kuncman; Magdalena Orzechowska; Konrad Stawiski; Michał Masłowski; Magdalena Ciążyńska; Leszek Gottwald; Tomasz Milecki; Jacek Fijuth
Journal:  Cancers (Basel)       Date:  2022-08-09       Impact factor: 6.575

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.